A US jury remains deadlocked in the high-stakes trial between Arm Holdings and Qualcomm over a licensing dispute involving Nuvia's chip designs, with deliberations ongoing.
In a closely watched legal battle, a US jury in Delaware is deadlocked in the trial between Arm Holdings and Qualcomm, a case that could have significant implications for the technology industry. The dispute centers around Qualcomm's acquisition of Nuvia, a chip design firm, and the subsequent use of Nuvia's technology, which Arm claims violates its licensing agreements.
Arm Holdings, a major player in the chip design industry, filed a lawsuit against Qualcomm, demanding the destruction of chip designs acquired from Nuvia. These designs are crucial to Qualcomm's strategy to expand into the personal computer market, a move that could challenge industry giants like Apple and Intel. The jury is tasked with answering three key questions: whether Nuvia breached its agreement with Arm, whether Qualcomm breached Nuvia's Arm license agreement, and whether Qualcomm's processor designs are properly licensed under its agreement with Arm.
The trial has seen high-profile testimonies, including from Qualcomm's CEO Cristiano Amon, who argued that Arm's actions have created uncertainty among Qualcomm's customers, including Samsung. Amon contended that Arm misled customers about the expiration of licensing agreements, which Arm denies. Arm's CEO Rene Haas testified that Qualcomm's use of Nuvia's technology is costing Arm $50 million annually in lost revenue.
The case has broader implications for the tech industry, as it could influence future intellectual property licensing agreements. Qualcomm argues that Arm is attempting to leverage the lawsuit to gain control over the smartphone chip market, while Arm insists it is merely enforcing its contractual rights. The jury's decision could impact Qualcomm's ability to continue using Nuvia's designs, which are integral to its new high-speed chips for AI laptops and other devices.
As the jury continues deliberations, the outcome remains uncertain, but the stakes are high for both companies and the broader tech industry.
Party City, a leading retailer in the party supplies industry, has filed for bankruptcy and announced the closure of all its stores, marking the end of nearly 40 years in business.
Honda and Nissan are in talks for a potential merger to address financial struggles and enhance competitiveness in the electric vehicle market.
Google has proposed to loosen its search engine agreements with companies like Apple to address antitrust concerns, while the US government pushes for more drastic measures.
The US FDA has approved Novo Nordisk's Alhemo, a groundbreaking treatment for hemophilia A and B with inhibitors, marking a significant advancement in hemophilia care.
The US FDA has declined to approve Lexicon Pharmaceuticals' Zynquista as an add-on treatment for type 1 diabetes and chronic kidney disease, prompting the company to shift focus to other drug candidates.
Sarepta Therapeutics Inc. has secured a $115.2 million verdict against Nippon Shinyaku Co. Ltd. for patent infringement related to its Duchenne muscular dystrophy drug, Vyondys 53.
Netflix has acquired the exclusive U.S. broadcasting rights for the FIFA Women's World Cup in 2027 and 2031, marking a significant move into live sports for the streaming giant.
Carnival Corporation & plc has reported record earnings for 2024, surpassing guidance and setting a positive outlook for 2025 with expected earnings growth and strong booking volumes.
United States Steel Corporation's stock has taken a hit following a weaker-than-expected fourth-quarter outlook, with projected losses and challenges in the steel market.